Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function

被引:34
作者
Lombardo R.M.R. [1 ,5 ]
Reina C. [2 ]
Abrignani M.G. [1 ]
Rizzo P.A. [1 ]
Braschi A. [3 ]
De Castro S. [4 ]
机构
[1] Department of Cardiology, Ospedale S. Antonio Abate, Trapani
[2] Trapani, Villa dei Gerani
[3] Department of Sport Medicine, University of Palermo
[4] Department of Cardiovascular and Respiratory Science, La Sapienza University, Rome
[5] Divisione di Cardiologia, Ospedale S. Antonio Abate, Trapani, 91016 Erice, Via Cosenza
关键词
Left Ventricular Ejection Fraction; Chronic Heart Failure; Carvedilol; Nebivolol; Carvedilol Group;
D O I
10.2165/00129784-200606040-00006
中图分类号
学科分类号
摘要
Background: β-Adrenoceptor antagonist (β-blocker) therapy results in a significant improvement in left ventricular (LV) systolic function and prognosis in patients with chronic heart failure. Both carvedilol and nebivolol produce hemodynamic and clinical benefits in chronic heart failure, but it is unknown whether their peculiar pharmacologic properties produce different effects on LV function. Objective: To assess the effects on LV function of nebivolol compared with carvedilol in patients with chronic heart failure and reduced LV systolic function. Methods: Seventy patients with a LV ejection fraction ≤40% and in New York Heart Association (NYHA) functional class II or III were randomly assigned to receive carvedilol or nebivolol therapy for 6 months. At baseline and after 6 months of treatment, all patients were assessed clinically and by biochemical and hematological investigation, ECG, 24-hour Holter monitoring, echocardiogram, measurement of ventilatory function, and a 6-minute walk test. Results: Compared with baseline values LV end-systolic volume decreased and LV ejection fraction increased in both the carvedilol (from 79 ± 38mL to 73 ± 43mL and from 33% ± 6% to 37% ± 11%) and the nebivolol group (from 72 ± 35mL to 66 ± 32mL and from 34% ± 7% to 38% ± 10%), although the between-group differences were not statistically significant. ECG data showed a decrease in resting HR in both groups (from 83 ± 20 bpm to 66 ± 11 bpm for carvedilol and from 81 ± 15 bpm to 65 ± 11 bpm for nebivolol; p < 0.001 vs baseline for both groups) but no difference in the PQ, QRS, and QT intervals. Hematologic (in particular, N-terminal pro-brain natriuretic peptide), Holter monitoring (with the exception of HR), and respiratory functional data did not show any significant variation in either group after 6 months' therapy. SBP and DBP decreased in both groups. A small reduction in mean NYHA functional class from baseline was seen in both groups (from 2.5 ± 0.5 to 2.2 ± 0.5 for carvedilol [p < 0.05] and from 2.3 ± 0.4 to 2.2 ± 0.5 for nebivolol [not significant]). The 6-minute walk test showed a trend toward an increase in the walking distance in both groups. During 6 months of treatment no significant differences in adverse events were observed between the groups. Conclusion: Nebivolol is as effective as carvedilol in patients with symptomatic chronic heart failure and reduced LV systolic function. © 2006 Adis Data Information BV. All rights reserved.
引用
收藏
页码:259 / 263
页数:4
相关论文
共 19 条
[1]  
Packer M., Bristow M.R., Cohn J.N., Et al., The effect of carvedilol on morbidity and mortality in patients with chronic heart failure, N Engl J Med, 334, pp. 1349-1355, (1996)
[2]  
The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): A randomized trial, Lancet, 353, pp. 9-13, (1999)
[3]  
Cockroft J.R., Chowenczyk P.H.J., Brett S.E., Et al., Nebivolol vasodilates human forearm vasculature: Evidence for L-arginin/NO dependent mechanism, J Pharmacol Exp Ther, 274, pp. 1067-1071, (1995)
[4]  
Brehm B.R., Wolf S.C., Bertsch D., Et al., Effects of nebivolol on proliferation and apoptosis on human coronary artery smooth muscle and endothelial cells, Cardiovasc Res, 49, pp. 430-439, (2001)
[5]  
Brehm B.R., Wolf S.C., Gorner S., Et al., Effect of nebivolol on left ventricular function in patients with chronic heart failure: A pilot study, Eur J Heart Fail, 4, pp. 757-763, (2002)
[6]  
Wolf S.C., Buck-Muller N., Gorner S., Et al., Influence of the beta-blocker nebivolol on the left ventricular function in patients with chronic heart failure, Med Klin, 98, pp. 1-6, (2003)
[7]  
Brune S., Schmidt T., Tebbe U., Et al., Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure, Angiology, 4, pp. 696-701, (1990)
[8]  
Nodari S., Metra M., Dei Cas L., Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension: A prospective, randomized, comparison of the long-term effects of atenolol vs nebivolol, Eur J Heart Fail, 5, pp. 621-627, (2003)
[9]  
Schiller N.B., Shah P.M., Crawford M., Et al., Recommendations for quantitation of the left ventricle by two-dimensional echocardiography, J Am Soc Echocardiogr, 2, 5, pp. 358-367, (1989)
[10]  
Quinones M.A., Otto C.M., Stoddard M., Et al., Recommendations for quantification of Doppler echocardiography: A report from the Doppler Quantification Task Force of the Nomenclature and Standards Committee of the American Society of Echocardiography, J Am Soc Echocardiogr, 15, pp. 167-184, (2002)